Hospital

Pharmacists guide evidence-based medication care as AI, regulation shifts, and new therapies rise.

ENVISION trial shows mitomycin intravesical solution after TURBT delivers durable control in recurrent NMIBC, with 72% event-free at 24 months.

Education, safety protocols, and evolving responsibilities are transforming the role of pharmacy technicians in cancer care.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on how pharmacy technicians can recognize when patients should be referred to a pharmacist or physician instead of self-treating with OTC products, and how to help patients avoid risks associated with combination products such as duplicate ingredients.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.

New CMS prior authorization timelines highlight major infrastructure gaps while underscoring the link between access, affordability, and medication adherence.

A hantavirus outbreak aboard a cruise ship is raising urgent concerns about the dangers of this rare but deadly rodent-borne virus.

The FDA approved the supplemental biologics license for the expansion of IVIG (immune globulin, intravenous) use to children 2 years and older with primary humoral immunodeficiency, enabling earlier treatment and infection protection.

Data from a large New York State analysis found that sickle cell disease hospitalizations are becoming more severe over time, with significant regional disparities in outcomes, costs, and access to specialized care.

FDA approval of orforglipron may expand access to obesity treatment by offering a more convenient oral GLP-1 therapy option.

Ambulatory pharmacists can address mental health gaps, tackle stigma and SDOH, and power collaborative care, improving adherence and patient quality of life.

During Hepatitis Awareness Month, learn why hepatitis B vaccination and one-time screening help prevent silent infection and cut liver cancer risk.

Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.

Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

Renee’ Acosta, RPh, MS, discusses recent developments in the OTC market and key considerations pharmacy staff should prioritize when guiding patients in selecting appropriate over-the-counter therapies.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

Data from COA highlight operationalizing novel therapies in community cancer care.

Pharmacists help prevent communication breakdowns and improve coordination across oncology care teams.

Emerging data regarding newly diagnosed AML found that the Endothelial Activation and Stress Index independently predicts early mortality and ICU admission during intensive induction chemotherapy.

The need for data-driven, multidisciplinary care and the critical role of pharmacists in managing the growing complexity of oncology treatment

Pharmacists are enabling the shift to outpatient bispecific antibody care through education, SOP development, and care coordination.

Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.

Harm reduction–based counseling frameworks for cannabis use during pregnancy and lactation can improve patient engagement, disclosure, and safety, with pharmacists playing a key role in implementation.

COA 2026 reveals how bispecific antibodies transform lymphoma care—outpatient workflows, SOPs, and infection vigilance shape safe BTCE delivery.

Postate cancer care shifts toward personalized, team-based management in an increasingly complex therapeutic landscape.